PDS Biotech to Join May 2024 Investor Conferences

PRINCETON, N.J., May 09, 2024 — PDS Biotechnology Corporation (Nasdaq: PDSB), a late-stage immunotherapy company, has announced its participation in two upcoming investor conferences in May 2024. The company, which specializes in innovative immunotherapy approaches for cancer treatment and infectious disease vaccines, is set to engage with investors and discuss its progress and future plans.

The first event is the Citizens JMP Life Sciences Conference, scheduled for May 13, 2024, at the New York Hilton Midtown in New York, NY. PDS Biotech will deliver a company presentation at 12:30 PM ET and engage in one-on-one meetings with investors. Interested parties can register for the presentation through the event's platform and coordinate individual meetings via their Citizens JMP representative.

The second event is A.G.P.'s Virtual Healthcare Company Showcase on May 21, 2024. PDS Biotech will partake in a fireside chat with A.G.P.’s Jim Molloy and Scott Henry at 10:00 AM ET. An archived replay of this discussion will be available on PDS Biotech’s website in the Investor Relations section following the event.

PDS Biotechnology is advancing its lead program aimed at treating advanced head and neck squamous cell cancers (HNSCC). The program features a proprietary combination of IL-12 fused antibody drug conjugate (ADC) PDS01ADC and T-cell activator Versamune® HPV, used in conjunction with a standard-of-care immune checkpoint inhibitor. The company believes that this combination has shown positive long-term survival results and tumor reduction, while also indicating favorable tolerability.

The mechanism behind this innovative treatment is described as an “inside-outside” approach. The PDS01ADC and Versamune® HPV therapy is designed to breach a tumor’s internal defenses and simultaneously generate potent, targeted killer T-cells to attack the tumor externally. Data from over 350 patients and ongoing clinical trials across various tumor types and treatment regimens have supported the potential effectiveness of this approach.

In addition to cancer immunotherapy, PDS Biotechnology is developing vaccines based on its Infectimune® technology. Pre-clinical studies have demonstrated that these vaccines can induce robust, durable neutralizing antibody responses, as well as powerful T-cell responses, including long-lasting memory T-cells.

PDS Biotechnology remains committed to transforming cancer treatment and contributing to the development of effective infectious disease vaccines, leveraging its innovative technology platforms. Further details about the company and its initiatives can be found on their website.